1. Yip ,W., T.Powell-Jackson,W.Chen,M.Hu,E,Fe et al 2014. Capitation combined with pay-for-performance improves antibiotic prescribing practices in rural China. Health Aff., 33: 502-510.
   CrossRef  |  PubMed  |  Direct Link  |  
2. Kennedy-Martin, T., B. D. Mitchell, K.S. Boye, W. Chen, B. H. Curtis et al, 2014. The health technology assessment environment in mainland china, japan, southkorea, and taiwan�implications for the evaluation of diabetes mellitus therapies. Value Health Reg.issue, 3: 108-116.
   CrossRef  |  Direct Link  |  
3. Chen, M., L. Wang, W. Chen, L. Zhang, H. Jiang and W. Mao, 2014. Does economic incentive matter for rational use of medicine? China's experience from the essential medicines program. PharmacoEconomics, 32: 245-255.
   CrossRef  |  Direct Link  |  
4. C. Daniel Mullins, C. O.Nneka,G.T. B.de Afaujo, W. Chen, J. X. Ales Tichopadet al, 2014. Guidance document: global pharmacoeconomic model adaption strategies. Value Health Reg.issue, 5: 7-13.
   CrossRef  |  Direct Link  |  
5. ZHANG, L., W. Lijie, C.Wen, M. Wenhui, J. Hongli, and F. Wenjun., 2013. Pharmaceutical utilization behaviors and cognition of medical professionals with the implementation of the essential medicines policies Chinese Health Resour., 16: 98-100.
   Direct Link  |  
6. Wenhui, M., Z. Luying, C. Wen, C.Mingsheng and J.Hongli 2013. Allocation and utilization of essential medicines at primary health care institutions. Chinese Health Res., 16: 95-97.
   Direct Link  |  
7. Mao.W,S.Tang andW.Chen, 2013. Does perverse economic incentive lead to the irrational uses of medicines? Expert Rev Pharmacoecon Outcomes Res., 13: 693-696.
   CrossRef  |  PubMed  |  Direct Link  |  
8. Jingjing, Z., F. Wenjun, H.G. Yunyu, and C. Wen., 2013. Economic burden of type 2 diabetes mellitus with nephropathy complications in China. Chinese Health Econom., 32: 32-34.
   Direct Link  |  
9. Wenhui, M.,L. Hua, C.Wen and J. Hongli 2012. Introduction of Australian drug pricing system and its revelation to Chinese drug regulation. BMC Health Serv Res., 15: 427-430.
10. Chi-Man, Y.W., C.H. William, C. Wen, H. Shanlian, M. Jin and M. Alan, 2012. Early appraisal of China's huge and complex health-care reforms. Lancet, 379: : 833-842.
    CrossRef  |  Direct Link  |  
11. Yip, W.C.M., W. Hsiao, Q. Meng, W. Chen and X. Sun, 2010. Realignment of incentives for health-care providers in China. Lancet, 375: 1120-1130.
    CrossRef  |  
12. WANG L.,C. Wen, 2010.. Comparison of governmental compensation methods for essential health care delivery in public hospitals. Chinese Health Resources 13: 255-257.
    Direct Link  |  
13. Wen C.,H.Jinlin 2009. Pharmacoeconomic evaluation of telbivudine vs. lamivudine in treating the patients with HBeAg-positive and negative chronic hepatitis B, Chin J Hepatol, 17: 569-573.
    Direct Link  |  
14. Yanyan M., W.Chen,H. Jianget al 2007. Analysis on medical expenditure containment related policy (2): Basic medical insurance policy. Chinese Health Resources 10: : 139-141.
15. Chen.,W.Chen,H. Jiang, 2007. Analysis on medical expenditure containment related policy (3): policy on drug expenditure containment. Chinese Health Resou., 10: 175-177.
    Direct Link  |  
16. Kangning B., Y.Gu, Wen Chenet al 2006. Cost-effectiveness analysis of oral vs. intravenous iron treatment for renal anemia patients. Chin J. Nephrol, 22: 596-600.
    Direct Link  |  
17. Kangning B., W.Chen and S.Hu 2005. Systematic evaluation of pharmacoeconomic literatures on domestic digestive system diseases. China Pharmacy 16: 278-280.
    Direct Link  |  
18. Wen C.,X.Ying and X.Lu., 2004. Organizing and financing urban employees`supplementary medical insurance Chin J Hosp Admin., 20: 648-653.
    Direct Link  |  
19. Chen W., H. Shanlian and Y.Xiaohua 2000. Cost-utility analysis of cefepime vs ceftazidime in treatment of patients with medium or severe pneumonia. J.Clinical Pharmac., 9: 237-241.
    Direct Link  |